Congress leader P. Chidambaram has slammed the government over prices of vaccines, and asked why the government is not invoking compulsary licensing.
The former finance minister said in a tweet, "Will those who justified the Covisheld prices of Rs 400 and 600 also justify the Covaxin prices of Rs 600 and 1200 announced today?"
"The government is standing (not helplessly) and silently endorsing the blatant profiteering and exploitation by the two manufacturers. Why is the government not invoking the provision of 'compulsory licensing'?" He said in another tweet.
Bharat Biotech has said its Covaxin will cost Rs 600 for state governments and Rs 1,200 for private hospitals, while the other vaccine maker, Serum Institute of India (SII), has said it will sell its Covishield developed by Oxford-AstraZeneca at Rs 400 a jab to states and Rs 600 to private hospitals.
Several chief ministers have raised red flag over the different pricing of vaccines and have asked for uniform pricing for all.
--IANS
miz/skp/
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)